{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"69"}]}],"title":"Doctor Office Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"22"}]}],"title":"Emergency Department Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"5"}]}],"title":"Hospital Admission"}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"description":"Number of participants who had any of the following types of Healthcare Resource Utilization (HRU): - a doctor office visit (non-study scheduled) - an emergency department visit - a hospitalization","groups":[{"description":"Luspatercept (ACE-536) was administered subcutaneously (SC) at a starting dose level of 1 mg/kg once every 21 days. Participants could be dose-titrated to 1.25 mg/kg, but the maximum total dose should not exceed 120 mg, total dose per administration during the Treatment Period, the Long-term Treatment Period, and Open-Label Treatment Period. BSC = Best Supportive Care","id":"OG000","title":"Luspatercept + BSC"},{"description":"Placebo (normal saline) was administered subcutaneously (SC) in volumes to match active treatment once every 21 days. BSC = Best Supportive Care","id":"OG001","title":"Placebo + BSC"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From informed consent signing (up to 12 weeks before start of treatment) to end of treatment (up to approximately 227 weeks)","title":"Number of Participants Who Utilized Healthcare Resources During Study","type":"SECONDARY","unitOfMeasure":"Participants"}